Best Stocks To Buy During Covid Pandemic
Best Stocks To Buy During Covid Pandemic: As you are probably aware, the COVID pandemic is once again knocking on the world’s door. We have seen earlier that the impact of the COVID epidemic falls on every sector of the economy. And the impact of the pandemic is widespread in the stock market as well. Even then, when COVID comes, money can be lost in the stock market, but money can also be made wisely at this time. It works both ways. If you are also thinking of investing your money in the stock market at this time, then you must read this article completely. In this article, you will know in detail about those stocks that can give you good returns in the time of COVID.
Whenever COVID comes, the shares of almost all companies start falling, but even during the COVID pandemic, some stocks continue to perform well and give good returns to their investors. Today we are going to learn about those stocks.
Glenmark Pharmaceuticals Ltd.
Incorporated in 1977. Glenmark Pharmaceuticals Ltd. is a mid-cap company operating in the pharma sector with a market capitalization of ₹ 11,968.16 crore. The current PE ratio is 14.41. The company’s annual revenue growth of 13.44% outperformed its three-year CAGR of 7.3%. In the fiscal year 2021-22, the company spent 2.42% of its operating revenue on interest expenses and 19.89% on employee costs.
The company reported a consolidated total income of ₹ 3,472.68 crore for the second quarter ended September 30, 2022, up 17.30% from the previous quarter’s total income of ₹ 2,960.44 crore and 10.79% from the same quarter last year’s total income of ₹ 3,134.38 crore. In the most recent quarter, the company reported a net profit after tax of ₹ 278.67 crore.
Aurobindo Pharma Ltd.
Incorporated in 1986. Aurobindo Pharma Ltd. It is a large-cap company operating in the pharmaceuticals sector with a market capitalization of ₹ 25,681.69 crore. The current PE ratio is 12.16. Annual sales at the company fell by 5.48%.The company witnessed revenue contraction for the first time in the last 3 years, and it also witnessed a QoQ revenue decline of 7.65%, which is the lowest in the last 3 years.
For the second quarter ended on September 30, 2022, the company reported a consolidated total income of ₹ 5,796.56 crore, down 7.65% from last quarter’s total income of ₹ 6,276.54 crore and down 4.01% from last year’s (2021-2022) same quarter total income of ₹ 6,038.50 crore. In the most recent quarter, the company reported a net profit after tax of ₹ 411.60 crore.
Dr. Reddy’s Laboratories Ltd.
It was incorporated in 1984. Dr. Reddy’s Laboratories Ltd. is a large-cap company operating in the pharmaceuticals sector with a market capitalization of ₹ 70,541.06 crore. The current PE ratio is 22.69. In the financial year 2021–2022, the company spent less than 1% of its operating revenues on interest expenses and 18.04% on employee costs.
The company reported a consolidated total income of ₹ 6,372.60 crore for the second quarter ended September 30, 2022, up 4.70% from the previous quarter’s total income of ₹ 6,086.80 crore and up 6.34% from the same quarter last year’s total income of ₹ 5,992.40 crore. The company reported a net profit after tax of ₹ 1,100.20 crore in the latest quarter.
ALSO READ
In a mutual fund, money is gathered from numerous individuals to buy securities such as stocks, bonds, money market instruments, and other assets. Asset management firms are in charge of managing mutual funds (AMCs). READ MORE
Cipla Ltd.
Incorporated in 1935. Cipla Ltd. is a large-cap company operating in the pharmaceuticals sector with a market capitalization of ₹ 86,829.34 crore. The current PE ratio is 33.47. Cipla Ltd.’s (the company’s) annual revenue growth of 13.48% outperformed its three-year CAGR of 9.3%. In the financial year 2021–2022, the company spent less than 1% of its operating revenues on interest expenses and 16.22% on employee costs.
The company reported a consolidated total income of ₹ 5,951.49 crore for the second quarter ended September 30, 2022, an increase of 8.63% from the previous quarter’s total income of ₹ 5,478.62 crore and a 6.65% increase from the same quarter last year’s total income of ₹ 5,580.47 crore. In the most recent quarter, the company reported a net profit after tax of ₹ 797.76 crore.
Sun Pharmaceutical Industries Ltd.
Incorporated in 1993. Sun Pharmaceutical Industries Ltd. is a large-cap company operating in the pharmaceuticals sector with a market capitalization of ₹ 240,269.40 crore. The current PE ratio is 58.54. The company’s annual revenue growth of 15.27% outperformed its three-year CAGR of 9.46%. Sun Pharmaceutical Industries Ltd. has spent less than 1% of its operating revenues on interest expenses and 18.89% on employee costs in the financial year 2021–22.
The company reported a consolidated total income of ₹ 11,037.50 crore for the second quarter ended September 30, 2022, up 2.54% from the previous quarter’s total income of ₹ 10,763.90 crore and 12.7% from the same quarter last year’s total income of ₹ 9,848.82 crore. The company reported a net profit after tax of ₹ 2,260.17 crore in the latest quarter.
Lupin Ltd.
It was incorporated in 1983. Lupin Ltd. is a large-cap company operating in the pharmaceuticals sector with a market capitalization of ₹ 33,359.47 crore. The current PE ratio is 489.21. In the financial year 2021–2022, the company spent less than 1% of its operating revenues on interest expenses and 18.22% on employee costs.
Lupin Limited reported a consolidated total income of ₹ 4,160.46 crore for the second quarter ended September 30, 2022, up 10.96% from the previous quarter’s total income of ₹ 3,749.40 crore and down.09% from the same quarter last year’s total income of ₹ 4,164.14 crore. In the most recent quarter, the company reported a net profit after tax of ₹ 134.47 crore.
Biocon Ltd.
Incorporated in 1978. Biocon Ltd. is a large-cap company operating in the pharmaceuticals sector with a market capitalization of ₹ 31,437.71 crore. The current PE ratio is 50.95. In the financial year 2021–2022, the company spent less than 1% of its operating revenues on interest expenses and 22.97% on employee costs.
Biocon Limited reported a consolidated total income of ₹ 2,384.20 crore for the second quarter ended September 30, 2022, up 7.52 percent from the previous quarter’s total income of ₹ 2,217.40 crore and 22.56 percent from the same quarter last year’s total income of ₹ 1,945.30 crore. In the most recent quarter, the company reported a net profit after tax of ₹ 110.10 crore.
Divi’s Laboratories Ltd.
It was incorporated in 1990. Divi’s Laboratories Ltd. is a large-cap company operating in the pharmaceuticals sector with a market capitalization of ₹ 90,609.74 crore. The current PE ratio is 30.28 and delivered an ROE of 25.24% in the financial year 2021–22, outperforming its five-year average of 20.75%. Company operating cash flow of ₹ 1911.8 crore is 0.65 times as large as the reported net profit of ₹ 2960.45 crore.
The company’s annual revenue growth of 29.04 percent outperformed its three-year CAGR of 20.93%. In the financial year 2021–22, Divi’s Laboratories Ltd. also witnessed a QoQ revenue decline of 17.43%, which is the lowest in the last 3 years.
The company reported a consolidated total income of ₹ 1,934.62 crore for the second quarter ended September 30, 2022, a 17.43 percent decrease from the previous quarter’s total income of ₹ 2,342.91 crore and a 3.59 percent decrease from the same quarter last year’s total income of ₹ 2,006.62 crore. In the most recent quarter, the company reported a net profit after tax of ₹ 493.60 crore.
Pfizer Ltd.
Incorporated in the year 1950, Pfizer Ltd. is a large-cap company operating in the pharmaceuticals sector with a market capitalization of ₹ 20,274.02 crore. The current PE ratio is 33.06, and the company has consistently increased ROE in the last 5 years, with the majority of profits being added to its reserves last year. Company Operating cash flow of ₹ 237.76 crore is 0.79 times that of the reported net profit of ₹ 299.57 crore, and the company has used ₹ 575.02 crore for investing activities, which is a YoY increase of 22.65%.
Pfizer Ltd.’s annual revenue growth of 15.26% outperformed its 3-year CAGR of 5.88%. In addition, in fiscal 2021-22, the company spent less than 1% of its operating revenues on interest expenses and 15.46% on employee costs.
The company reported a standalone total income of ₹ 661.71 crore for the second quarter ended September 30, 2022, up 8.31% from the previous quarter’s total income of ₹ 610.92 crore and up 1.60% from the same quarter last year’s total income of ₹ 651.29 crore. In the most recent quarter, the company reported a net profit after tax of ₹ 311.07 crore.
ALSO READ
Tata Motors Share Price Target 2023, 2024, 2025, 2026, 2027, 2028 & 2030
If you are looking for “Tata Motors share price target” for upcoming years then you are in the right place. If you want to invest in the auto sector then Tata Motors may be a good option. READ MORE
Conclusion
Pandemics such as COVID-19 affect the supply of active ingredients and materials (mainly from China) as well as the import and export of goods. The service and manufacturing sectors also have negative impacts, both medium- and long-term in nature.
The Indian pharmaceutical industry, on the other hand, has grown at a cumulative growth rate (CAGR) of 11% in the domestic market and 16% in exports in recent years. The pharma business has outperformed expectations in response to the worldwide emergency, providing medicines to more than 150 countries in addition to meeting every single domestic requirement. Due to all these reasons, growth is being seen in the pharma sector during the pandemic, and shares of pharma companies also give good returns in such times.
